Do Depressed Patients With Diabetes Experience More Side Effects When Treated With Citalopram Than Their Counterparts Without Diabetes?

2009 ◽  
Vol 11 (5) ◽  
pp. 186-196 ◽  
Author(s):  
Charlene Bryan ◽  
Thomas Songer ◽  
Maria Mori Brooks ◽  
Michael E. Thase ◽  
Bradley Gaynes ◽  
...  
Keyword(s):  
Side Effects ◽  
Depressed Patients ◽  
Patients With Diabetes

scholarly journals Use of fluoxetine in patients with diabetes mellitus

1995 ◽  
Vol 19 (9) ◽  
pp. 553-554
Author(s):  
Gill Salmon
Keyword(s):  
Diabetes Mellitus ◽  
At Risk ◽  
Side Effects ◽  
Pharmaceutical Companies ◽  
Important Group ◽  
Patients With Diabetes

Although pharmaceutical companies report side effects that may occur with use of their medications, little data on specific groups of patients that may be at risk of particular side effects is available (Katz et al, 1991). Patients with diabetes mellitus form an important group for psychiatrists since the occurrence of depression is relatively common with this group and guidance on its treatment is lacking.

scholarly journals Malfunction in GABA and Glutamate as Pathways to Depression: A Review of the Evidence

2009 ◽  
Vol 1 ◽  
pp. CMT.S3481 ◽  
Author(s):  
Christopher F Sharpley
Keyword(s):  
Experimental Data ◽  
Side Effects ◽  
Disease Burden ◽  
Potential Treatment ◽  
Pharmacological Treatments ◽  
Neurotransmitter Systems ◽  
Antidepressant Medications ◽  
Depressed Patients ◽  
Few Data

With nearly one fifth of the population experiencing depression sometime during their lives, plus the recent finding that depression rivals smoking in its association with mortality, the search for effective pharmacological treatments for depression remains urgent. However, despite this heavy disease burden upon society, the various waves of antidepressants developed in the last 40 years have shown significant side effects and little specific efficacy over placebo. One potential treatment may be via re-establishment of glutamate and GABA neurotransmitter systems that have been shown to malfunction in depressed patients. The literature describing possible causal links between GABA and/or glutamate malfunction and depression is reviewed, plus those studies which provide experimental data to confirm this hypothesis. While there is plausible support for the links between malfunction of these neurotransmitters and depression, few data exist yet regarding development of effective antidepressant medications based upon these findings.

Dibenzepin and Amitriptyline in the Treatment of Depression

1971 ◽  
Vol 118 (546) ◽  
pp. 523-524 ◽  
Author(s):  
M. Y. Ekdawi
Keyword(s):  
Side Effects ◽  
Antidepressant Drug ◽  
Comparative Trial ◽  
Tricyclic Antidepressant ◽  
Pharmacological Properties ◽  
Double Blind ◽  
Depressed Patients ◽  
Treatment Of Depression ◽  
Significant Difference

Dibenzepin hydrochloride is a new tricyclic antidepressant drug with pharmacological properties midway between those of imipramine and amitriptyline. In a double-blind comparative trial, J. M. Fielding (Med. J. Australia, 1969, 1, 614) found no significant difference in the speed of the effect of the two drugs in depressed patients. He reported that side-effects rated subjectively by patients were maximal before starting on the drugs and tended to decrease with time. The following trial was accordingly staged.

A Placebo Controlled Trial of Viloxazine with and without Tranquillizers in Depressive Illness

1975 ◽  
Vol 3 (3) ◽  
pp. 207-213 ◽  
Author(s):  
R V Magnus
Keyword(s):  
Side Effects ◽  
Clinical Effect ◽  
Controlled Trial ◽  
Depressive Illness ◽  
Antidepressant Effect ◽  
Double Blind ◽  
Depressed Patients ◽  
Crossover Studies

Two double-blind four-way crossover studies are reported, comparing the antidepressant effect of 14-day courses of: viloxazine, viloxazine with a tranquillizer either perphenazine or diazepam or tranquillizer alone, against a placebo. In one study the antidepressant effect of viloxazine at a dose of 150 mg daily was statistically greater than that of placebo, whilst in the second study viloxazine was statistically superior to diazepam (15 mg daily). In depressed patients with a clear anxiety component, viloxazine alone seemed preferable to a combination with a tranquillizer as such a combination did not produce an enhanced clinical effect and the incidence of side-effects was possibly increased. Viloxazine was generally well tolerated and side-effects, when they occurred, were generally a mild upper gastro-intestinal disturbance.

Litigation and the toxicity of psychotropic drugs

1996 ◽  
Vol 13 (3) ◽  
pp. 88-89 ◽  
Author(s):  
Brian E Leonard
Keyword(s):  
Side Effects ◽  
Psychotropic Drugs ◽  
Medical Negligence ◽  
Pharmaceutical Firms ◽  
Depressed Patients ◽  
Legal Procedures

All drugs have side effects and given the increase in litigation for medical negligence that has occurred in Ireland in recent years, it would not be surprising to find that clinicians prescribing psychotropic drugs would also become the target for legal procedures if they fail to warn the patient about the possible side effects and toxicity of the drugs they are prescribing. The two extremes of the problem may be illustrated by the litigation carried out against some pharmaceutical firms and prescribers of benzodiazepines and the lack of such proceedings resulting from deaths of depressed patients who take an overdose of a prescribed antidepressant.

scholarly journals Using the analytic hierarchy process to prioritize alternative medicine: selecting the most suitable medicine for patients with diabetes

2016 ◽  
Vol 5 (1) ◽  
pp. 67 ◽  
Author(s):  
Mohammed A. Balubaid ◽  
Mohammed A. Basheikh
Keyword(s):  
Type 2 Diabetes ◽  
Decision Making ◽  
Side Effects ◽  
Analytic Hierarchy Process ◽  
Newly Diagnosed ◽  
Analytic Hierarchy ◽  
Patients With Diabetes ◽  
The Analytic Hierarchy Process ◽  
Hierarchy Process

<p>Diabetes mellitus (DM) is emerging as a major public health problem in Saudi Arabia and this disease affects the Middle East in general. The analytic hierarchy process (AHP) was performed to select the most appropriate oral hypoglycemic agent for use as a monotherapy among newly diagnosed patients with type 2 diabetes. Eight important criteria resulted from the hierarchy structure: side effects, chronic disease, background scientific evidence, age, weight, cost, education level, and gender. The involvement of these different factors reveals that treating diabetes is a multi-criteria decision making (MCDM) problem. Thus, AHP was used because it is one of the most common MCDM tools. This project developed a mathematical decision-making model that prioritizes the available medications for patients with diabetes in terms of the aforementioned criteria. Oral type 2 diabetes medications (metformin, pioglitazone, sitagliptin, and glimepiride) were ranked 1st, 2nd, 3rd and 4th, respectively; their weights were 48.42%, 24.47%, 13.61% and 13.50%, respectively. Thus, metformin is recommended because it has the highest weight. Side effects were the most important factor affecting drug selection. The AHP provides an overall ranking to aid with final decisions. Unquestionably, the results of this project, or at least the proposed methodology, facilitate the decision-making process, which is important because it assists the decision maker in determining which oral drug to choose for newly diagnosed patients with diabetes.</p>

Intravenous Tranquillization with ECT

1975 ◽  
Vol 127 (6) ◽  
pp. 604-608 ◽  
Author(s):  
Joan Gomez ◽  
Peter Dally
Keyword(s):  
Side Effects ◽  
Recovery Time ◽  
Memory Impairment ◽  
Depression And Anxiety ◽  
Convulsive Therapy ◽  
Depressed Patients ◽  
Retrograde Memory ◽  
High Level ◽  
Electro Convulsive Therapy

SummaryForty depressed in-patients for whom electro-convulsive therapy had been prescribed were rated before treatment on depression and anxiety scales. Side effects, post-operative agitation and retrograde memory impairment were assessed in each patient after each of several treatments. Results were compared when no tranquillizer was given and when either diazepam or haloperidol was administered intravenously immediately before the anaesthetic. It was found than when ECT was given without tranquillization, the incidence and severity of post-operative agitation and of side effects were significantly greater in those patients with a high level of anxiety before treatment. Both diazepam and haloperidol were found to be effective in subduing agitation and side effects in anxious, depressed patients, but with diazepam recovery time was longer.

Amitriptyline: Comparison of Three Different Dosage Schedules in Neurotic Depression

1979 ◽  
Vol 135 (1) ◽  
pp. 73-76 ◽  
Author(s):  
Domenico De Maio ◽  
Alessandro Levi-Minzi
Keyword(s):  
Single Dose ◽  
Side Effects ◽  
Lower Incidence ◽  
Depression Scale ◽  
The Third ◽  
Depressed Patients ◽  
Self Rating

SummaryThree groups of neurotic depressed patients were treated with amitriptyline, one group receiving the customary three daily doses, another a single dose in the morning, and the third a single dose at night. All three groups showed significant decrements of total scores on the Hamilton Scale for Depression and the Zung Self-Rating Depression Scale without significant differences. Patients taking the drug at night showed a lower incidence of side effects.

Sign in / Sign up

Export Citation Format

Share Document